Please login to the form below

Not currently logged in
Email:
Password:

TT701

This page shows the latest TT701 news and features for those working in and with pharma, biotech and healthcare.

Transition takes on Lilly muscle-boosting drug

Transition takes on Lilly muscle-boosting drug

The big pharma company pockets just $1m upfront from the deal, although Transition could pay up to $100m in milestones if the small-molecule drug - called TT701 - eventually reaches the market. ... TT701 is a selective androgen receptor modulator (SARM)

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Transition Therapeutics with the out-licence of the phase II ready selective androgen receptor modulator TT701 to Transition. ... 105.5. Eli Lilly/ Transition Therapeutics. Licence agreement. For TT701 a selective androgen receptor modulator in P2 for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics